Latest news with #SaudiNationalInstituteofHealth
Mid East Info
6 days ago
- Business
- Mid East Info
KFSHRC Pioneering Clinical Trials and Gene Therapy Across the Region - Middle East Business News and Information
As part of Saudi Arabia's broader biotechnology transformation under Vision 2030, King Faisal Specialist Hospital & Research Centre (KFSHRC) solidified its role as the Kingdom's leading Clinical Trials hub in 2024 — conducting 52.4% of all active Clinical Trials nationwide, according to the Saudi National Institute of Health. This milestone reflects the sustained success of KFSHRC's Clinical Trials Transformation Initiative, launched in 2021 to build an integrated, patient-centered research ecosystem. By the end of 2024, the hospital had recorded 701 active research proposals, representing an 8% increase over the previous year. In Riyadh alone, research approvals rose by 20%, demonstrating growing alignment between scientific discovery and clinical care delivery. KFSHRC's research growth was matched by key innovation milestones. In 2024, it became the first in Saudi Arabia to locally produce CAR-T cells — a major step toward national self-sufficiency in advanced therapies. It also delivered a breakthrough in hemophilia care, using one-time gene therapy to restore clotting function in eight patients, eliminating preventive treatment and significantly improving quality of life. These advancements align closely with Saudi Arabia's Vision 2030 and National Biotechnology Strategy, which designate biotechnology as a national priority sector — aiming to localize therapeutic development, accelerate innovation, and establish global leadership by 2040. Complementing its scientific leadership, KFSHRC has also invested in public engagement, launching awareness campaigns in high-traffic public venues to promote Clinical Trials literacy and reduce misconceptions around participation. It is noteworthy that KFSHRC has been ranked first in the Middle East and Africa and 15th globally among the world's top 250 Academic Medical Centres for the third consecutive year, and recognised as the most valuable healthcare brand in the Kingdom and the Middle East, according to the 2025 Brand Finance rankings. Additionally, it was included in the World's Best Smart Hospitals list for 2025 by Newsweek magazine.
Associated Press
10-03-2025
- Health
- Associated Press
Saudi Arabia Clinical Trials Market & Regulations Insight 2025 - A US$ 200 Million Market Opportunity
The 'Saudi Arabia Clinical Trials Market, Ongoing Clinical Trials by Company, Indication, Phase & Regulations Insight 2025" report has been added to offering. Report Highlights Saudi Arabia Clinical Trials Market Opportunity: US$ 200 Million Comprehensive Insight on Clinical Trials Studies in Saudi Arabia: > 400 Studies Clinical Trials Studies by Indication, Phase & Sponsor Regulatory Framework & Clinical Trials Guidelines Insight on Domestic CRO Operating in Saudi Arabia: 15 CRO Overview on Existing Healthcare Infrastructure & Medical Professionals Like Doctors, Dentist, Nurses Saudi Arabia is making significant strides in expanding its clinical research sector, aligning with the broader objectives of Vision 2030, which prioritizes scientific advancement and innovation. The Saudi government is actively enhancing research education and investing in clinical trials to improve healthcare outcomes. A key player in this transformation is the Saudi National Institute of Health (NIH), which has launched several initiatives to raise the quality and quantity of research conducted within the country. These efforts include establishing cutting-edge research facilities, fostering an environment where clinical trials can thrive, and setting new benchmarks for excellence. By strengthening its focus on clinical trials, Saudi Arabia aims to develop medical treatments tailored to its population's specific genetic and health profiles. This is particularly important given the high prevalence of conditions such as diabetes and cardiovascular diseases, which require targeted treatment approaches. Addressing these health challenges through locally relevant clinical research ensures that therapies are better suited to the Saudi population, improving both patient outcomes and the overall healthcare system. A closer look at the therapeutic areas of focus reveals that oncology, endocrinology, cardiology, and infectious diseases dominate Saudi Arabia's clinical trial landscape. These fields have attracted significant attention due to their widespread impact on public health. Pharmaceutical companies play a crucial role in this ecosystem, serving as the primary sponsors of most clinical trials, particularly multinational studies that require extensive resources and collaboration. Meanwhile, local researchers are actively involved in studies that focus specifically on the Saudi population, addressing region-specific health concerns. Geographically, the majority of clinical trial sites are concentrated in urban centers, with Riyadh serving as the leading hub for research activities. The Makkah region and the Eastern Province also play significant roles, reflecting a broader trend where research efforts are primarily centered in areas with well-established medical infrastructure and access to specialized expertise. This concentration of research activity enables more efficient coordination of trials and facilitates collaborations between healthcare institutions, regulatory bodies, and industry stakeholders. As Saudi Arabia's clinical research landscape continues to develop, there has been a noticeable rise in the number of clinical trial applications under review. The Saudi Food and Drug Authority (SFDA) is working diligently to strengthen its regulatory framework, ensuring that all studies meet stringent safety and efficacy standards. This regulatory progress is crucial as the country seeks to attract more international multicenter trials, allowing it to integrate into the global clinical research ecosystem. The SFDA's efforts include refining approval processes, implementing robust monitoring systems, and ensuring compliance with international best practices. These improvements are particularly vital as Saudi Arabia moves toward more sophisticated trial designs, including precision medicine approaches and innovative drug development strategies. Additionally, the country is placing greater emphasis on translational research, bridging the gap between laboratory discoveries and real-world clinical applications. By fostering a research-friendly environment and maintaining high regulatory standards, Saudi Arabia is positioning itself as a key player in the global clinical trials landscape, driving advancements that will shape the future of healthcare both regionally and beyond. Key Topics Covered: 1. Saudi Arabia Clinical Trials Market Outlook 1.1 Current Scenario 1.2 Future Growth Outlook 2. Saudi Arabia Pharmaceutical Market Analysis 2.1 Overview 2.2 Regulatory Framework 2.3 Branded v/s Generic Drugs Availability 3. Saudi Arabia Clinical Trials Overview 3.1 by Phase 3.2 by Sponsors 4. Saudi Arabia Clinical Trials Insight by Company, Indication & Phase 4.1 Phase I 4.2 Phase I/II 4.3 Phase I/IIIB 4.4 Phase II 4.5 Phase II/III 4.6 Phase III 4.7 Phase IV 4.8 Phase BE 5. Saudi Arabia Clinical Trials Regulatory Framework & Guidelines 5.1 Overview 5.2 Drug Safety Monitoring Initiatives 5.3 Regulations For Conducting Clinical Trials on Drugs 5.4 Regulation For Drugs Approval 5.5 Guidelines For Investigational New Drugs (IND) 6. Healthcare Infrastructure & Manpower in Saudi Arabia 7. Saudi Arabia Clinical Trials Market Dynamics 7.1 Drivers & Opportunities 7.2 Challenges & Restraints 8. Clinical Research Organizations Operating in Saudi Arabia ArabMed CRO Baahith Balsam Clinical Research CLINLIA ClinServ International CTI KAU Med CRO MCT CRO Mesned Monitoring Force Gulf Limited PDC CRO Phoenix Clinical Research RAY CRO SALA CRO SGS For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. View source version on Laura Wood, Senior Press Manager For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 INDUSTRY KEYWORD: HEALTH CLINICAL TRIALS SOURCE: Research and Markets Copyright Business Wire 2025. PUB: 03/10/2025 08:10 AM/DISC: 03/10/2025 08:10 AM
